UTHR Quote, Financials, Valuation and Earnings

AptarGroup has a net margin of 41.27% compared to United Therapeutics's net margin of 11%. United Therapeutics's return on equity of 19.26% beat AptarGroup's return on equity of 14.16%.

United Therapeutics has a consensus price target of $335.33, signalling upside risk potential of 9.5%. On the other hand AptarGroup has an analysts' consensus of $148.43 which suggests that it could grow by 18.85%. Given that AptarGroup has higher upside potential than United Therapeutics, analysts believe AptarGroup is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.544, which suggesting that the stock is 45.563% less volatile than S&P 500. In comparison AptarGroup has a beta of 0.577, suggesting its less volatile than the S&P 500 by 42.257%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AptarGroup offers a yield of 1.09% to investors and pays a quarterly dividend of $0.45 per share. United Therapeutics pays -- of its earnings as a dividend. AptarGroup pays out 36.45% of its earnings as a dividend. AptarGroup's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

United Therapeutics quarterly revenues are $748.9M, which are smaller than AptarGroup quarterly revenues of $909.3M. United Therapeutics's net income of $309.1M is higher than AptarGroup's net income of $100M. Notably, United Therapeutics's price-to-earnings ratio is 15.79x while AptarGroup's PE ratio is 31.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 6.38x versus 2.99x for AptarGroup. Usually stocks with elevated PS ratios are considered overvalued.

The Cooper Companies has a net margin of 41.27% compared to United Therapeutics's net margin of 11.54%. United Therapeutics's return on equity of 19.26% beat The Cooper Companies's return on equity of 5.02%.

United Therapeutics has a consensus price target of $335.33, signalling upside risk potential of 9.5%. On the other hand The Cooper Companies has an analysts' consensus of $112.01 which suggests that it could grow by 19.87%. Given that The Cooper Companies has higher upside potential than United Therapeutics, analysts believe The Cooper Companies is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.544, which suggesting that the stock is 45.563% less volatile than S&P 500. In comparison The Cooper Companies has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.236%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Companies offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. United Therapeutics pays -- of its earnings as a dividend. The Cooper Companies pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $748.9M, which are smaller than The Cooper Companies quarterly revenues of $1B. United Therapeutics's net income of $309.1M is higher than The Cooper Companies's net income of $117.5M. Notably, United Therapeutics's price-to-earnings ratio is 15.79x while The Cooper Companies's PE ratio is 47.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 6.38x versus 4.81x for The Cooper Companies. Usually stocks with elevated PS ratios are considered overvalued.

Liquidia has a net margin of 41.27% compared to United Therapeutics's net margin of -520.57%. United Therapeutics's return on equity of 19.26% beat Liquidia's return on equity of -168.37%.

United Therapeutics has a consensus price target of $335.33, signalling upside risk potential of 9.5%. On the other hand Liquidia has an analysts' consensus of $25.30 which suggests that it could grow by 127.93%. Given that Liquidia has higher upside potential than United Therapeutics, analysts believe Liquidia is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.544, which suggesting that the stock is 45.563% less volatile than S&P 500. In comparison Liquidia has a beta of 0.220, suggesting its less volatile than the S&P 500 by 78.016%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Liquidia pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $748.9M, which are larger than Liquidia quarterly revenues of $4.4M. United Therapeutics's net income of $309.1M is higher than Liquidia's net income of -$23.2M. Notably, United Therapeutics's price-to-earnings ratio is 15.79x while Liquidia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 6.38x versus 52.59x for Liquidia. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 41.27% compared to United Therapeutics's net margin of 25.23%. United Therapeutics's return on equity of 19.26% beat Pfizer's return on equity of 4.63%.

United Therapeutics has a consensus price target of $335.33, signalling upside risk potential of 9.5%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Pfizer has higher upside potential than United Therapeutics, analysts believe Pfizer is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.544, which suggesting that the stock is 45.563% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. United Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

United Therapeutics quarterly revenues are $748.9M, which are smaller than Pfizer quarterly revenues of $17.7B. United Therapeutics's net income of $309.1M is lower than Pfizer's net income of $4.5B. Notably, United Therapeutics's price-to-earnings ratio is 15.79x while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 6.38x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.